ATE493978T1 - Behandlung von autoimmunerkrankungen - Google Patents

Behandlung von autoimmunerkrankungen

Info

Publication number
ATE493978T1
ATE493978T1 AT99957017T AT99957017T ATE493978T1 AT E493978 T1 ATE493978 T1 AT E493978T1 AT 99957017 T AT99957017 T AT 99957017T AT 99957017 T AT99957017 T AT 99957017T AT E493978 T1 ATE493978 T1 AT E493978T1
Authority
AT
Austria
Prior art keywords
treatment
autoimmune diseases
intravenously
administering
amino acid
Prior art date
Application number
AT99957017T
Other languages
English (en)
Inventor
Thomas B Bryan
Original Assignee
Thomas B Bryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas B Bryan filed Critical Thomas B Bryan
Application granted granted Critical
Publication of ATE493978T1 publication Critical patent/ATE493978T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99957017T 1998-06-19 1999-06-02 Behandlung von autoimmunerkrankungen ATE493978T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9000598P 1998-06-19 1998-06-19
US09/223,069 US6103748A (en) 1998-06-19 1998-12-29 Method of treating an autoimmune disorder
PCT/US1999/012232 WO1999065479A1 (en) 1998-06-19 1999-06-02 Method of treating an autoimmune disorder

Publications (1)

Publication Number Publication Date
ATE493978T1 true ATE493978T1 (de) 2011-01-15

Family

ID=26781225

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957017T ATE493978T1 (de) 1998-06-19 1999-06-02 Behandlung von autoimmunerkrankungen

Country Status (7)

Country Link
US (2) US6103748A (de)
EP (1) EP1085862B1 (de)
AT (1) ATE493978T1 (de)
AU (1) AU760993B2 (de)
CA (1) CA2338533C (de)
DE (1) DE69943107D1 (de)
WO (1) WO1999065479A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder
US6489345B1 (en) * 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
KR20030070147A (ko) * 2001-01-30 2003-08-27 아지노모토 가부시키가이샤 염증성 질환 치료 예방제
JP4300753B2 (ja) * 2001-05-31 2009-07-22 味の素株式会社 貧血抑制剤及び食欲抑制剤
US20060029647A1 (en) * 2004-02-09 2006-02-09 Friesen Kim G Composition and method for use in cartilage affecting conditions
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
WO2006049286A1 (ja) * 2004-11-02 2006-05-11 Ajinomoto Co., Inc. アレルギー性疾患予防・治療剤
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
DE602005005454T2 (de) * 2005-04-25 2009-04-30 Sahltech I Göteborg AB Behandlung von Einschlusskörper-Myositis
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US7700083B2 (en) * 2005-10-24 2010-04-20 Kevin Meehan Skin care composition for accelerated production of collagen proteins and method of fabricating same
IL172896A0 (en) * 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
US8389739B1 (en) 2006-10-05 2013-03-05 Orphagen Pharmaceuticals Modulators of retinoid-related orphan receptor gamma
WO2011008510A2 (en) 2009-06-30 2011-01-20 E. I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase
AR078829A1 (es) 2009-10-30 2011-12-07 Du Pont Plantas y semillas con niveles alterados de compuesto de almacenamiento, construcciones relacionadas y metodos relacionados con genes que codifican proteinas similares a las aldolasas bacterianas de la clase ii del acido 2,4- dihidroxi-hept-2-eno-1,7-dioico
EP2542682A2 (de) 2010-03-03 2013-01-09 E.I. Du Pont De Nemours And Company Pflanzensamen mit veränderten speichersubstanzkonzentrationen, zugehörige konstrukte und verfahren mit für oxidoreduktase-motiv-polypeptide kodierenden genen
AU2011271497A1 (en) 2010-07-01 2013-01-10 E. I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding PAE and PAE-like polypeptides
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
WO2018226987A1 (en) 2017-06-07 2018-12-13 The Regents Of The University Of California Compositions for treating fungal and bacterial biofilms and methods of using the same
US10682325B2 (en) 2017-08-14 2020-06-16 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting
JP2021527670A (ja) 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． 筋肉中の脂肪浸潤の治療のための組成物及び方法
WO2020117755A1 (en) 2018-12-03 2020-06-11 The Regents Of The University Of California Compositions and methods for treating biofilms
US11334352B1 (en) 2020-12-29 2022-05-17 Kpn Innovations, Llc. Systems and methods for generating an immune protocol for identifying and reversing immune disease
US12109176B1 (en) 2023-04-20 2024-10-08 Thomas Bryan Effect of glycerol on biofilm forming bacteria and fungi that changes the microbes sensitivity to pro and anti-biofilm non-toxic, non-bonded plasma amino acids and amino acid derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB839711A (en) * 1956-11-19 1960-06-29 Andrew Andor Recsei Process for the treatment of alcoholic and non-alcoholic beverages
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
ATE54826T1 (de) * 1985-10-23 1990-08-15 Mulli Kurt Nachf Gmbh Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
CA2190107A1 (en) * 1994-05-11 1995-11-23 Secant Pharma, Llc Compositions for treatment of chronic inflammatory diseases
DE4431175A1 (de) * 1994-09-01 1996-04-11 Medico Pharma Vertriebs Gmbh Neue, Chelatbildner enthaltende Arzneimittel
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6103748A (en) * 1998-06-19 2000-08-15 Bryan; Thomas B. Method of treating an autoimmune disorder

Also Published As

Publication number Publication date
EP1085862B1 (de) 2011-01-05
AU4328199A (en) 2000-01-05
CA2338533A1 (en) 1999-12-23
WO1999065479A1 (en) 1999-12-23
EP1085862A4 (de) 2008-07-23
AU760993B2 (en) 2003-05-29
US6103748A (en) 2000-08-15
CA2338533C (en) 2009-11-24
US6274612B1 (en) 2001-08-14
DE69943107D1 (de) 2011-02-17
EP1085862A1 (de) 2001-03-28

Similar Documents

Publication Publication Date Title
DE69943107D1 (de) Behandlung von autoimmunerkrankungen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
AP1398A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives.
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HUP9802556A1 (hu) Eljárás és készítmény kötőszöveti kapcsolódások gyógyítására és helyreállítására
EA200100721A1 (ru) Производное габапентина для предупреждения и лечения висцеральной боли
PT998287E (pt) Utilizacao de levobupivacaina
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
EA200401473A1 (ru) Предотвращение и лечение амилоидогенного заболевания
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
DE60139466D1 (de) Behandlung von diabetes
ATE252897T1 (de) Verwendung von p-aminophenolderivaten zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von neurodegenerativen erkrankungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
DE69736180D1 (de) Behandlung von manischen erkrankungen
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69621786D1 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
DE50003730D1 (de) Caspase 8-inhibitoren zur immunsuppression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties